The Health Department has
released updated Pharmaceutical
Benefits Advisory Committee
outcomes for nintedanib and
evolocumab from the Mar 2015
PBAC meeting, as well as for
simeprevir and nivolumab from the
Jul 2015 meeting.
For details see pbs.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.